Paratek gets takeover speculation

 

• Paratek Pharmaceuticals (NASDAQ:PRTK) is up 20% in Tuesday afternoon trading amid a report that the biopharma is a takeout target.
• Betaville Intelligence is reporting that those familiar with the situation say a private equity firm is the leading suitor.
• Paratek's (PRTK) marketed products include the antibiotics Nuzyra (omadacycline) and Seysara (sarecycline).
• https://seekingalpha.com/news/3949564-paratek-pharmaceuticals-up-20-on-takeout-speculation-report